FierceBiotech 21. Apr. 2026 Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
FierceBiotech 16. Apr. 2026 Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
FierceBiotech 6. Apr. 2026 With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine
FierceBiotech 1. Apr. 2026 Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
FierceBiotech 1. Apr. 2026 Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
FierceBiotech 23. März 2026 Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
FierceBiotech 19. März 2026 Pfizer adds to Seagen scrap heap with another early cancer candidate cull
FierceBiotech 12. März 2026 Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
FierceBiotech 4. März 2026 Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations
FierceBiotech 25. Feb. 2026 After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
FierceBiotech 6. Feb. 2026 Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
FierceBiotech 4. Feb. 2026 Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
FierceBiotech 21. Jan. 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech 9. Jan. 2026 Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential
FierceBiotech 9. Dez. 2025 Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug
FierceBiotech 5. Dez. 2025 Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability